Document and Entity Information
Document and Entity Information | Sep. 19, 2023 |
Cover [Abstract] | |
Amendment Flag | true |
Entity Central Index Key | 0001419041 |
Document Type | 8-K/A |
Document Period End Date | Sep. 19, 2023 |
Entity Registrant Name | FORTE BIOSCIENCES, INC. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-38052 |
Entity Tax Identification Number | 26-1243872 |
Entity Address, Address Line One | 3060 Pegasus Park Dr. |
Entity Address, Address Line Two | Building 6 |
Entity Address, City or Town | Dallas |
Entity Address, State or Province | TX |
Entity Address, Postal Zip Code | 75247 |
City Area Code | (310) |
Local Phone Number | 618-6994 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, $0.001 par value |
Trading Symbol | FBRX |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Amendment Description | This Current Report on Form 8-K/A is being filed by Forte Biosciences, Inc. (the “Company”) as a second amendment (the “Second Amendment”) to the Current Report on Form 8-K filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) on September 20, 2023 (the “Original 8-K”), as amended by Amendment No. 1 filed by the Company with the SEC on September 26, 2023 (the “First Amendment”). This Second Amendment is being filed to disclose, in accordance with Item 5.07(d) of Form 8-K, the Company’s decision as to how frequently the Company will include a stockholder advisory vote on the compensation of its named executive officers. Except as described herein, no other changes have been made to the Original 8-K or the First Amendment. |